Intravenous DDAVP and Factor VIII-von Willebrand Factor Concentrate for the Treatment and Prophylaxis of Bleedings in Patients With von Willebrand Disease Type 1,2 and 3

Abstract

The current standard set of von Willebrand factor (VWF) parameters used to differentiate type 1 from type 2 VWD include bleeding times (BTs), factor VIII coagulant activity (FVIII:C), VWF antigen (VWF:Ag), VWF ristocetine cofactor activity (VWF:RCo), VWF collagen binding activity (VWF:CB), ristocetine induced platelet aggregation (RIPA), and analysis of VWF multimers in low and high resolution agarose gels and the response to DDAVP. The BTs and RIPA are normal in asymptomatic carriers of a mutant VWF allele, in dominant type 1, and in recessive type 2N VWD, and this category has a normal response of VWF parameters to DDAVP. The response of FVIII:C is compromised in type 2N VWD. The BTs and RIPA are usually normal in type Vicenza and mild type 2A VWD, and these two VWD variants show a transiently good response of BT and VWF parameters followed by short in vivo half life times of VWF parameters. The BTS are strongly prolonged and RIPA typically absent in recessive severe type 1 and 3 VWD, in dominant type 2A and in recessive type 2C (very likely also 2D) VWD and consequently associated with low or absent platelet VWF, and no or poor response of VWF parameters to DDAVP. The BTs are prolonged and RIPA increased in dominant type 2B VWD, that is featured by normal platelet VWF and a poor response of BT and functional VWF to DDAVP. The BTs are prolonged and RIPA decreased in dominant type 2A and 2U, that all have low VWF platelet, very low VWF:RCo values as compared to VWF:Ag, and a poor response of functional VWF to DDAVP. VWD type 2M is featured by the presence of all VWF multimers in a low resolution agarose gel, normal or slightly prolonged BT, decreased RIPA, a poor response of VWF:RCo and a good response of FVIII and VWF:CB to DDAVP and therefore clearly in between dominant type 1 and 2U. The existing recommendations for prophylaxis and treatment of bleedings in type 2 VWD patients with FVIII/VWF concentrates are mainly derived from pharmocokinetic studies in type 3 VWD patients. FVIII/VWF concentrates should be characterised by labelling with FVIII:C, VWF:RCo, VWF:CB and VWF multimeric pattern to determine their safety and efficacy in prospective management studies. As the bleeding tendency is moderate in type 2 and severe in type 3 VWD and the FVIII:C levels are near normal in type 2 and very low in type 3 VWD patients. Proper recommendations of FVIII/VWF concentrates using VWF:RCo unit dosing for the prophylaxis and treatment of bleeding episodes are proposed and has to be stratified for the severity of bleeding, the type of surgery either minor or major and for type 2 and type 3 VWD as well.

Keywords

von Willebrand factor von Willebrand disease Ristocetine cofactor activity von Willebrand collagen binding activity Bleeding time DDAVP Hemate-P

References

Sadler JE. A revised classification of von Willebrand disease. Thromb Haemostas 1994;71: 520-520.

Sadler JE , Mannucci PM , Berntorp E , et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemostas 2000;84: 160-160.

Michiels JJ , Berneman ZW , Gadisseur A , et al. Clinical, laboratory and molecular classification of hereditary recessive severe type 1 and 3 von Willebrand disease (VWD), asymptomatic heterozygous type 1 versus bloodgroup O related von Willebrand factor (VWF) deficiency, and dominant type 1 VWD. Clin Applied Thromb Hemostas 2005; this issue.

Michiels JJ , Berneman ZW , Gadisseur A , et al. Clinical, laboratory and molecular classification of hereditary von Willebrand diseases type 2A, 2B, 2M, 2U (unclassifiable), 2C, 2D, 2E and 2N: A critical appraisal and personal experiences. Clin Applied Thromb Hemostas 2005; this issue.

Michiels JJ , Van De Velde A , Van Vliet HHDM , et al. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: Diagnostic and therapeutic implications. Sem Thromb Hemostas 2002;28: 111-111.

Schneppenheim R , Budde U , Ruggeri ZM. A molecular approach to the classification of von Willebrand disease. Baillière’s Clinl Haematol 2001;14: 281-281.

Federici AB , Mazurier C , Berntorp E , et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: Results of a multicenter European study. Blood 2004;103: 2032-2032.

Favaloro EJ , Smith J , Petinos P , et al. Laboratory testing for von Willebrand’s disease: An assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. Thromb Haemostas 1999;82: 1276-1276.

Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA) detection of von Willebrand disease (VWD) and discrimination of VWD subtypes depends on collagen source. Thromb Haemostas 2000;83: 127-127.

10.

Neugebauer BM , Goy C , Budek I , Setitz R. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium and high multimers of von Willebrand factor. Sem Thromb Hemostas 2002;28: 139-139.

11.

Favaloro EJ , Bukuya M , Martinelli T , et al. A comparative multi-laboratory assessment of three factor/von Willebrand factor concentrates. Thromb Haemostas 2002;87: 466-466.

12.

Italian Working Group . Spectrum of von Willebrand’s disease: A study of 100 cases. Br J Haematol 1977;35: 101-101.

13.

Fressinaud E , Veyradier A , Truchaud F , et al. Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases. Blood 1998:91: 1325-1325.

14.

Fressinaud E , Veyradier A , Sigaud M , et al. Therapeutic monitoring of von Willebrand disease: Interest and limits of a platelet analyzer at high shear rate. Br J Haematol 1999;106: 777-777.

15.

Raboniwitz I , Tuley EA , Mancuso DJ , et al. Von Willebrand disease type B: A missence mutation selectively abolishes ristocetine-induced von Willebrand binding to platelet glycoprotein Ib. Proc Natl Acad Sci 1992;89: 9846-9846.

16.

Revel-Vilk S , Schmugge M , Carcao MD , et al. Desmopressin (DDAVP) resposiveness in children with von Willebrand disease. J Pediatr Hematol Oncol 2003;25: 874-874.

17.

Eikenboom JCJ , Matsushita T , Reitsma PH , et al. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood 1996;88: 2433-2433.

18.

Bodo I , Katsumi A , Tuley EA , et al. Type 1 von Wilebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: A possible general mechanism for dominant mutations of oligomeric proteins. Blood 2001;98: 2973-2973.

19.

Castaman G , Eikenboom JCJ , Missiaglia E , Rodeghiero F. Autosomal dominant type 1 von Willebrand disease due to G3639T mutation (C1130) in exon 26 of von Willebrand gene: Description of five Italian families and evidence for a founder effect. Br J Haematol 2000;108: 876-876.

20.

Batlle J , Lopez-Fernandez MF , Campos M , et al. The heterogeneity of type IIA von Willebrand’s disease. Blood 1986;68: 1207-1207.

21.

Batlle J , Lassieri J , Villamor AF , et al. Proteolytic rocessing of von Willebrand factor subunit: Heterogeneity in type IIA von Willebrand disease. Ann Hematol 1994;68: 111-111.

22.

Castaman G , Rodeghiero F , Lattuada A , Mannucci PM. A new variant of von Willebrand disease (type II I) with a normal degree of proteolytic cleavage of von Willebrand factor. Thromb Res 1992;65: 343-343.

23.

Mazurier C , Manucci PM , Parquet-Gernez A , et al. Investigation of a case of subtype IIC von Willebrand disease: Characterisation of the variability of this subtype. Am J Hematol 1986;22: 301-301.

24.

Eikenboom JCJ , Reitsma PH , Peerlinck KJM , Briët E. Recessive inheritance of von Willebrand’s disease. Lancet 1993;341: 982-982.

25.

Schneppenheim R , Budde U , Krey S , et al. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1. Thromb Haemostas 1996;76: 598-598.

26.

Mazurier C. Von Willebrand disease masquerading as haemophilia A. Thromb Haemostas 1992;67: 391-391.

27.

Mazurier C , Goudemand J , Hilbert L , et al. Type 2N von Willebrand disease: Clinical manifestations, pathophysiology. Laboratory diagnosis and molecular biology. Clin Haematol Baillière’s 2001;14: 337-337.

28.

Mazurier C , Gaucher C , Joriuex S , Goudemand M. Biological effect of desmopressin in eight patients with type 2N (‘Normandy’) von Willebrand disease. Br J Haematol 1994;88: 849-849.

29.

Mannucci PM. Recommended protocol for the study of ex vivo biological effects of virus-inactivated plasma concentrates with von Willebrand disease. Thromb Haemostas 1992;68: 84-84.

30.

Mannucci PM , Tenconi PM , Castaman G , Rodeghiero R. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: A crossover randomized trial. Blood 1992;9: 3130-3130.

31.

Fukui H , Nishino M , Terada S , et al. Hemostatic effect of a heat-treated factor VIII concentrate (Haemate-P) in von Willebrand’s disease. Blut 1988;56: 171-171.

32.

Lethagen S , Berntorp E , Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII-von Willebrand factor concentrates in von Willebrand’s disease type III. Ann Hematol 1992;65: 253-253.

33.

Goudemand J , Mazurier C , Marey A , et al. Clinical and biological evaluation in von Willebrand’s disease of a von Willebrand factor concentrate with low factor VIII activity. Br J Haematol 1992;80: 214-214.

34.

Menache D , Aronson DL , Darr F , Montgomery RR , and the Cooperative Study Group . Pharmacokinetics of von Willebrand factor andfactor VIIIC in patients with severe von Willebrand disease (type 3): Estimation of the rate of fctor VIIIC synthesis. Br J Haematol 1996;94: 740-740.

35.

Menache D , Aronson DL. New treatments of von Willebrand disease: Plasma derived vonWillebrand factor concentrates. Thromb Haemostas 1997;78: 566-566.

36.

Ver Elst K , Van Vliet HHDM , Kappers-Klunne MC , Leebeek FWG. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease. Thromb Haemostas 2004;92: 67-67.

37.

Auerswald G , Eberspächer B , Engl W , et al. Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated facor VIII/von Willebrand factor concentrate (ImmunateR). Sem Thromb Hemostas 2002;28: 203-203.

38.

Mannucci PM , Chediak J , Bymes W , et al , and the Alphanate Study Group . Treatment of von Willebrand disease with high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter study. Blood 2002;99: 450-450.

39.

Michiels JJ , Berneman ZN , Van Der Planken M , et al. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). Blood Coagul Fbribolysis 2004;15: 323-323.

40.

Mannucci PM. Treatment of von Willebrand’s disease. N Engl J Med 2004;351: 683-683.

41.

Mannucci PM , Moia M , Rebulla P , et al. Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor. Am J Hematol 1987;25: 55-55.

42.

Castillo R , Monteaguda J , Escolar G , et al. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients. Blood 1991;7: 1901-1901.